tradingkey.logo
tradingkey.logo
Suchen

COSCIENS Biopharma Inc

CSCI
Zur Watchlist hinzufügen
2.720USD
0.0000.00%
Handelsschluss 07/02, 13:00ETKurse um 15 Minuten verzögert
8.64MMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über COSCIENS Biopharma Inc Unternehmen

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

COSCIENS Biopharma Inc Informationen

BörsenkürzelCSCI
Name des UnternehmensCOSCIENS Biopharma Inc
IPO-datumDec 19, 1995
CEOMs. Anna Biehn
Anzahl der mitarbeiter- -
WertpapierartOrdinary Share
GeschäftsjahresendeDec 19
AddresseC/O Norton Rose Fulbright Canada Llp
StadtTORONTO
BörseThe Toronto Stock Exchange
LandCanada
PostleitzahlM5K 1E7
Telefon18439003201
Websitehttps://www.cosciensbio.com/
BörsenkürzelCSCI
IPO-datumDec 19, 1995
CEOMs. Anna Biehn

Führungskräfte von COSCIENS Biopharma Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Ulrich Kosciessa
Dr. Ulrich Kosciessa
Director
Director
1.85K
--
Mr. Robert A. Seager
Mr. Robert A. Seager
Director
Director
--
--
Ms. Nicola Ammer
Ms. Nicola Ammer
Senior Vice President - Clinical Development, Chief Medical Officer
Senior Vice President - Clinical Development, Chief Medical Officer
--
--
Dr. Matthias Gerlach
Dr. Matthias Gerlach
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
--
--
Mr. Giuliano La Fratta
Mr. Giuliano La Fratta
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
--
--
Mr. Michel Regnier
Mr. Michel Regnier
Senior Vice President, Chief Technology Officer
Senior Vice President, Chief Technology Officer
--
--
Mr. Ronald W. (Ronnie) Miller
Mr. Ronald W. (Ronnie) Miller
Director
Director
--
--
Mr. Peter H. Puccetti
Mr. Peter H. Puccetti
Chairman of the Board, Interim Chief Executive Officer
Chairman of the Board, Interim Chief Executive Officer
--
--
Mr. David Spear
Mr. David Spear
Director
Director
--
--
Mr. Anthony J. Giovinazzo
Mr. Anthony J. Giovinazzo
Director
Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Ulrich Kosciessa
Dr. Ulrich Kosciessa
Director
Director
1.85K
--
Mr. Robert A. Seager
Mr. Robert A. Seager
Director
Director
--
--
Ms. Nicola Ammer
Ms. Nicola Ammer
Senior Vice President - Clinical Development, Chief Medical Officer
Senior Vice President - Clinical Development, Chief Medical Officer
--
--
Dr. Matthias Gerlach
Dr. Matthias Gerlach
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
--
--
Mr. Giuliano La Fratta
Mr. Giuliano La Fratta
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
--
--
Mr. Michel Regnier
Mr. Michel Regnier
Senior Vice President, Chief Technology Officer
Senior Vice President, Chief Technology Officer
--
--

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von COSCIENS Biopharma Inc?

Die fünf größten Anteilseigner von COSCIENS Biopharma Inc sind: Dr. Ulrich Kosciessa

Wie viele Institutionen halten Anteile an COSCIENS Biopharma Inc (CSCI)?

Mit Stand vom 2026Q1 halten 31 Institutionen Anteile an COSCIENS Biopharma Inc, mit einem Gesamtmarktwert von etwa 257.26K, was 8.08% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -38426.00 gestiegen.